Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.
about
Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterizationImmucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytesMolecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiencyEnzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimesDeoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblastsThe metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiencyB cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosineErythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytesMitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient miceLoop-tryptophan human purine nucleoside phosphorylase reveals submillisecond protein dynamics.Conformational states of human purine nucleoside phosphorylase at rest, at work, and with transition state analoguesMechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells.The acquired immunodeficiency syndrome (AIDS)Nelarabine in the treatment of refractory T-cell malignant diseases.Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblastsMutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate poolsPossible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylaseRemote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase.Expression of the high-affinity purine nucleobase transporter in mutant mouse S49 cells does not require a functional wild-type nucleoside-nucleobase transporterHuman purine nucleoside phosphorylase and adenosine deaminase: gene transfer into cultured cells and murine hematopoietic stem cells by using recombinant amphotropic retroviruses.Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cellsIncomplete nucleoside transport deficiency with increased hypoxanthine transport capability in mutant T-lymphoblastoid cells.Proposed explanation for S-adenosylhomocysteine hydrolase deficiency in purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyltransferase-deficient patientsPurinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts.Cloning of human purine-nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli.Deoxycytidine deaminase-deficient Escherichia coli strains display acute sensitivity to cytidine, adenosine, and guanosine and increased sensitivity to a range of antibiotics, including vancomycin.Overview of possible relation of defects in purine metabolism to immune deficiency.Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells.Enzymes of the purine metabolism: inhibition and therapeutic potential.Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.Compartmentation of guanine nucleotide precursors for DNA synthesisGuanine for DNA synthesis. A compulsory route through ribonucleotide reductase.
P2860
Q24634661-1B6B7E40-A895-4ABA-BDD4-B9B771C1BE23Q24635226-6C89FBAD-58F4-45AD-9FA8-EC1FEB233391Q24669781-CCB5841D-9743-4943-95A1-BE1E34AA3E66Q28240827-EEB0213C-3F79-432E-BB92-DBE3794C52E5Q28361665-564DD0D1-8158-410D-8AFA-5511C6ED057AQ28366279-707B6B7C-BEF5-4B52-8369-A6BEBF34D49FQ28366641-7986356A-E78B-4FCB-8936-259BB1ADCB77Q28367127-794FB500-55FC-4572-BBAC-EA1074275B7FQ28590225-A3B2F093-A562-4463-BE0C-06597D375B94Q33405379-12ECC5DF-DDF6-4FAB-943F-092325EC812EQ33706528-6C7D8759-6197-4900-B183-E883E49B5730Q34274622-A3C85ABA-1DD5-43D9-B219-729F79D1F1D9Q34521424-FAD5E224-D08E-4104-BF58-951B71FBE478Q34559575-5F1BC585-A929-4DC4-9ED9-F292279B4831Q34614378-D8DE223D-E5FC-4452-B127-921E596A046AQ35350889-795A4559-3462-4D48-A777-9672D2282B04Q36300440-032F3CDC-3626-45C9-A1AE-8B9BB8568566Q36632125-D583BAD1-D998-4071-AEF6-49523218936CQ36832795-5D469C5D-DD48-45F4-88E4-218F99356C69Q36835425-8AFC8B62-3284-4AD3-8F25-FE5477361FDBQ36890260-A3F2E973-7895-4313-9347-AC4DEB3E713CQ36912460-C989CFB8-CB9D-4126-8303-566B6966B6A5Q36996403-ED1EF764-1741-4759-9690-A4A4B7856157Q37017801-5B48D4D0-36E5-4D28-8EA3-CE612FF5A878Q37341964-346BADE8-1457-411E-9CD5-C106C95BDA4FQ39259649-94C90F8C-4813-4E15-A652-64A272D67C47Q39850209-9D1302BA-6721-48C8-8279-A8B2B4E91E61Q40650216-B0C7064C-6CD9-4A0B-BAA1-4CDCE6198416Q40712361-2B6131EC-464F-40CA-8F91-A5F875566B5DQ41194286-3E54398E-57CA-405A-BBFD-C99614A28EA6Q41246020-4CC1CC93-B5F8-4318-8DA1-28C9B621BD60Q41858420-18F8F64B-9926-483A-9C40-D4A51BBFD172
P2860
Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 1979
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Isolation and characterization ...... for immunodeficiency disease.
@en
Isolation and characterization ...... for immunodeficiency disease.
@nl
type
label
Isolation and characterization ...... for immunodeficiency disease.
@en
Isolation and characterization ...... for immunodeficiency disease.
@nl
prefLabel
Isolation and characterization ...... for immunodeficiency disease.
@en
Isolation and characterization ...... for immunodeficiency disease.
@nl
P2093
P2860
P356
P1476
Isolation and characterization ...... for immunodeficiency disease.
@en
P2093
P2860
P304
P356
10.1073/PNAS.76.3.1074
P407
P577
1979-03-01T00:00:00Z